Tempus AI TEM is expanding its presence in precision medicine through collaborations, which may support future revenue growth. In line with this, Tempus entered an expanded multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy developed by Moderna and Merck and evaluated with KEYTRUDA in patients with resected stage IIB-IV melanoma and other cancers. Under the collaboration, Tempus will coordinate the collection and transfer of tumor tissue and blood samples for next-generation sequencing (NGS) and, subject to regulatory approvals, provide NGS services to support therapy design and manufacturing.
Tempus extended its data partnership with Recursion Pharmaceuticals, Inc. RXRX through November 2029. As part of the extension, the companies amended the original agreement’s annual license fees, replacing discretionary payments of up to $84 million over the next two years with committed payments totaling $42 million over the next three years. Under a separate agreement, Recursion also granted Tempus a non-exclusive, worldwide license to its proprietary RNA Foundation Model, TxFM.
Tempus partnered with Angiosarcoma Awareness, Inc. to advance data-driven research into angiosarcoma, a rare and aggressive cancer. The collaboration will leverage Tempus’ analytical resources and approximately 600 de-identified patient records with paired DNA and RNA sequencing data and available clinical information to deepen understanding of the disease.
Peer Update
Doximity DOCS announced an integration with Aledade, a physician-led leader in value-based care. The agreement will integrate Doximity’s HIPAA-compliant Clinical AI Suite, including its Scribe ambient notetaking tool and Ask clinical AI assistant, into Aledade Assist, an EHR overlay that provides clinical insights at the point of care.
Natera NTRA entered a national partnership with Susan G. Komen, the world’s leading breast cancer organization. Together, the companies aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera will serve as the 2026 Premier National Series Sponsor of the Susan G. Komen Race for the Cure and MORE THAN PINK Walk events. Through this, Natera will help raise awareness of breast health, support patients and survivors and advance Komen’s mission to save lives.
TEM’s Stock Price Performance
In the past year, Tempus’ shares have lost 24.9% compared with the industry’s 5.7% decline.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 6.73X compared with the industry average of 4.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus’ loss per share estimate for 2026 has remained unchanged.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tempus AI, Inc. (TEM): Free Stock Analysis Report
Natera, Inc. (NTRA): Free Stock Analysis Report
Recursion Pharmaceuticals, Inc. (RXRX): Free Stock Analysis Report
Doximity, Inc. (DOCS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).